Getinge Announces Preliminary Results for Third Quarter 2013
GETINGE, Sweden -- October 8, 2013
Getinge’s consolidated profit before tax for the third quarter 2013 is
expected to amount to 560-570 MSEK, which materially deviates from the
expectations indicated by the market consensus estimate.
The weaker earnings statement is primarily attributable to the following
- unfavorable product mix within the Critical Care division
- time delay in cost synergies related to the TSS acquisition
- the US Medical Device Tax and negative exchange-rate effects
For the full year, the organic volume growth is still expected to exceed last
year and amount to approximately 3-4 %. Profit before tax for the full year is
estimated to total at 3000 – 3200 MSEK when adjusted for restructuring
expenses and other nonrecurring expenses.
This announcement will be followed by a conference call at 10.00 AM CET today,
hosted by Johan Malmquist, CEO Getinge Group and Ulf Grunander, CFO Getinge
Getinge will issue its full Q3 report for 2013 on October 15th at 1:00 PM CET.
To participate, please call:
Sweden: +46 (0)8 5065 3938
UK: +44 (0)20 3427 1905
09.45 Call the conference number
11.00 End of conference
A recorded version of the conference will be accessible for five working days
at the following number:
Sweden: +46 (0)8 5051 3897
UK: +44 (0)20 3427 0598
US: +1 347 366 9565
GETINGE GROUP is a leading global provider of products and systems that
contribute to quality enhancement and cost efficiency within healthcare and
life sciences. We operate under the three brands of ArjoHuntleigh, GETINGE and
MAQUET. ArjoHuntleigh focuses on patient mobility and wound management
solutions. GETINGE provides solutions for infection control within healthcare
and contamination prevention within life sciences. MAQUET specializes in
solutions, therapies and products for surgical interventions, interventional
cardiology and intensive care.
The information is such that Getinge AB must disclose in accordance with the
Swedish Securities Market Act and/or the Financial Instruments Trading Act.
This information was brought to you by Cision http://news.cision.com
Johan Malmquist, +46 10 335 55 33
Ulf Grunander, +46 10 335 55 80
Press spacebar to pause and continue. Press esc to stop.